Below, we describe a pharmacogenetics technique which allows to selectively and reversibly inactivate LC neurons making use of Designer Receptors Exclusively Activated by Designer Medication (DREADD). We display the expression in the hM4Di DREADD may be limited to noradrenergic LC neurons Which the amount of LC inhibition is often adjusted by adapt